证券代码：688013 证券简称：天臣医疗 公告编号：2025-048 天臣国际医疗科技股份有限公司 2025 年半年度募集资金存放与实际使用情况的专项报告 （一）实际募集资金金额及到账时间 天臣医疗经中国证券监督管理委员会《关于同意天臣国际医疗科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2020]2020 号）核准，公司向社 会公开发行人民币普通股（A 股）2,000.00 万股，每股面值为人民币 1.00 元，发 行价格为人民币 18.62 元∕股，股款以人民币缴足，计人民币 372,400,000.00 元， 扣除承销费等发行费用（不含本次公开发行股票发行费用可抵扣增值税进项税额） 人民币 48,605,308.54 元，本公司募集资金净额为人民币 323,794,691.46 元。上述 资金于 2020 年 9 月 23 日到位，经中天运会计师事务所（特殊普通合伙）审验， 并出具中天运[2020]验字第 90052 号《验资报告》。 （二）募集资金使用和节余情况 本年度公司对募集资金项目共投入 41,584,918.69 元，其中"营销网络及信息 化建设项目"本期投入 93,084.00 ...

天臣国际医疗科技股份有限公司 2025 年度"提质增效重回报"行动方案半年度评估报告 为践行"进一步提升上市公司质量和投资价值"，更好发挥主体责任，回报投 资者，天臣国际医疗科技股份有限公司（以下简称"天臣医疗"或"公司"）于 2025 年 5 月 29 日在上海证券交易所网站（www.sse.com.cn）披露了《天臣医疗关于 2024 年度"提质增效重回报"行动方案的评估报告暨 2025 年度"提质增效重回报"行 动方案》，以不断增强投资者获得感和投资信心。 2025 年上半年，公司根据行动方案积极落实相关举措并认真评估实施效果， 公司于 2025 年 8 月 26 日召开了第二届董事会第二十八次会议审议通过了《2025 年"提质增效重回报"行动方案半年度评估报告》，现将行动方案半年度实施情况 报告如下： 一、专注做强公司主业，提升经营效率 2025年上半年，面对竞争加剧的市场环境，公司秉持长期主义发展理念，持 续深化国内国外双轮发展策略，聚焦超微创、电动智能、集约式智能手术平台及 执行末端等领域的核心技术研发创新，通过强化技术创新与产品迭代，提升业务 拓展效能，并不断优化内部运营管理，有力支撑了公司业务 ...

证券代码：688013 证券简称：天臣医疗 公告编号：2025-049 本事项尚需提交公司 2025 年第三次临时股东会审议。 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 （1）会计师事务所名称：公证天业会计师事务所（特殊普通合伙） （2）成立日期：公证天业创立于 1982 年，是全国首批经批准具有从事证券、期 货相关业务资格及金融业务审计资格的会计师事务所之一。2013 年 9 月 18 日，转制 为特殊普通合伙企业。 天臣国际医疗科技股份有限公司 关于续聘 2025 年度审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟续聘的会计师事务所名称：公证天业会计师事务所（特殊普通合伙）（以 下简称"公证天业"） （3）组织形式：特殊普通合伙企业 （4）注册地址：无锡市太湖新城嘉业财富中心 5-1001 室 （5）执行事务合伙人/首席合伙人：张彩斌 （6）截至 2024 年末，公证天业合伙人数量 59 人，注册会计师人数 349 人，签 署过证券服务业务审计报告的注册会计师人 ...

证券代码：688013 证券简称：天臣医疗 公告编号：2025-051 天臣国际医疗科技股份有限公司 关于召开2025年第三次临时股东会的通知 网络投票起止时间：自2025 年 9 月 12 日 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第三次临时股东会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 9 月 12 日 14 点 30 分 召开地点：苏州工业园区东平街 278 号会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 至2025 年 9 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 1 股东会 ...

公司代码：688013 公司简称：天臣医疗 天臣国际医疗科技股份有限公司 2025 年半年度报告 1 / 201 天臣国际医疗科技股份有限公司 2025 年半年度报告 天臣国际医疗科技股份有限公司 2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细描述公司在生产经营过程中可能面临的相关风险，敬请查阅"第三节 管理层讨论与分析"之"四、风险因素"部分内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人陈望宇、主管会计工作负责人田国玉及会计机构负责人（会计主管人员）田国 玉声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 截至 2025 年 6 月 30 日，公司期末母公司报表中可供分配利润为 93,964,559.42 元（未经审计）， 2025 年半年度实现归属于母公司所有者的净利润为 48,211,574.09 元。 公司 2025 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tianchen Medical, which closed at 45.25 yuan, up 6.07%, with a rolling PE ratio of 68.35 times and a total market value of 3.672 billion yuan [1] - The average PE ratio for the medical device industry is 55.91 times, with a median of 40.36 times, positioning Tianchen Medical at the 94th rank within the industry [1] - As of March 31, 2025, Tianchen Medical has 4,443 shareholders, an increase of 68 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Tianchen Medical focuses on the research, innovation, production, and sales of high-end surgical anastomosis devices, with main products including endoscopic anastomosis devices, tubular anastomosis devices, linear cutting anastomosis devices, pouch anastomosis devices, and linear suturing devices [1] - The company has been recognized with the title of "Suzhou Intelligent Workshop - Minimally Invasive Surgical Anastomosis Device Intelligent Manufacturing Workshop" [1] - In the latest quarterly report for Q1 2025, the company achieved an operating income of 65.8461 million yuan, a year-on-year increase of 9.34%, and a net profit of 13.1867 million yuan, a year-on-year increase of 16.16%, with a gross profit margin of 58.46% [1]

Company Performance - Tianchen Medical's stock price reached a historical high, increasing by 4.45% to 44.56 yuan, with a trading volume of 1.0861 million shares and a transaction value of 48.1418 million yuan, resulting in a turnover rate of 1.34% [1] - The latest total market capitalization of the company in A-shares is 3.616 billion yuan, with the same amount for the circulating market capitalization [1] - The company's Q1 report shows a revenue of 65.8461 million yuan, a year-on-year increase of 9.34%, and a net profit of 13.1867 million yuan, a year-on-year increase of 16.16%, with basic earnings per share of 0.1700 yuan and a weighted average return on equity of 2.38% [1] Industry Overview - The pharmaceutical and biotechnology industry, to which Tianchen Medical belongs, has an overall increase of 0.83%, with 359 stocks rising and 5 stocks hitting the daily limit, including Xintian Pharmaceutical and Lingkang Pharmaceutical [1] - Conversely, 116 stocks in the industry experienced declines, with the largest drops seen in Duorui Pharmaceutical, ST Weiming, and Jinkai Biotechnology, with declines of 5.47%, 4.89%, and 3.66% respectively [1] Margin Trading Data - As of August 22, the latest margin trading balance for Tianchen Medical is 109 million yuan, with a financing balance of 109 million yuan, reflecting an increase of 11.89% or 11.5670 million yuan over the past 10 days [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tianchen Medical, which closed at 42.66 yuan with a 3.42% increase, resulting in a rolling PE ratio of 64.44 times and a total market value of 3.462 billion yuan [1] - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, positioning Tianchen Medical at the 91st rank within the industry [1] - As of March 31, 2025, Tianchen Medical has 4,443 shareholders, an increase of 68 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Tianchen Medical focuses on the research, innovation, production, and sales of high-end surgical staplers, with key products including endoscopic staplers, tubular staplers, linear cutting staplers, pouch staplers, and linear suturing staplers [1] - The company has been recognized with the title of "Suzhou Intelligent Workshop - Minimally Invasive Surgical Stapler Intelligent Manufacturing Workshop" [1] - In the latest quarterly report for Q1 2025, the company achieved an operating revenue of 65.8461 million yuan, a year-on-year increase of 9.34%, and a net profit of 13.1867 million yuan, reflecting a year-on-year growth of 16.16%, with a gross profit margin of 58.46% [1]

Core Viewpoint - Tianchen Medical (688013) has shown a positive stock performance with a closing price of 41.25 yuan on August 21, 2025, reflecting a 3.44% increase, despite a net outflow of main funds [1][2]. Group 1: Stock Performance and Trading Data - On August 21, 2025, Tianchen Medical's stock price increased by 3.44% with a trading volume of 22,200 hands and a total transaction amount of 89.30 million yuan [1]. - The main funds experienced a net outflow of 10.25 million yuan, accounting for 11.47% of the total transaction amount, while retail investors saw a net inflow of 5.84 million yuan, representing 6.54% of the total [1][2]. - Over the past five days, the stock has fluctuated, with the highest closing price being 41.25 yuan and the lowest at 39.04 yuan [2]. Group 2: Financing and Margin Trading Data - As of August 21, 2025, the financing balance for Tianchen Medical was 106 million yuan, with a net financing purchase of 1.42 million yuan [3]. - The company had no short-selling activity, with a margin trading balance remaining at 106 million yuan [3]. Group 3: Company Financials and Industry Comparison - Tianchen Medical reported a main revenue of 65.84 million yuan for Q1 2025, a year-on-year increase of 9.34%, and a net profit of 13.19 million yuan, up 16.16% year-on-year [5]. - The company has a total market value of 3.348 billion yuan, which is significantly lower than the industry average of 12.244 billion yuan [5]. - Key financial metrics include a price-to-earnings ratio of 63.47, a price-to-book ratio of 6.3, and a gross margin of 58.46%, all of which indicate a competitive position within the medical device industry [5].

Market Performance - The Shanghai Composite Index rose by 0.13%, with 38 stocks reaching historical closing highs [1] - Among the tradable A-shares, 2,170 stocks increased in price, accounting for 40.08%, while 3,091 stocks decreased, making up 57.09% [1] - The average price of stocks that reached historical highs was 90.53 yuan, with 6 stocks priced over 100 yuan and 12 stocks priced between 50 and 100 yuan [1] Sector Analysis - The sectors with the highest concentration of stocks reaching historical highs included electronics (10 stocks), automotive (5 stocks), and machinery equipment (5 stocks) [1] - Notable stocks with significant price increases included Chuangyitong (15.01%), Guomai Culture (11.37%), and Zhejiang Haideman (10.28%) [2][3] Capital Flow - The total net inflow of main funds into stocks reaching historical highs was 1.036 billion yuan, with 23 stocks experiencing net inflows [2] - The stocks with the highest net inflows included Zhinanzhen (429 million yuan), Beifang Huachuang (247 million yuan), and Xinye Sheng (222 million yuan) [2] - Conversely, 12 stocks saw net outflows, with the largest outflows from Fuyao Glass (347 million yuan), Heertai (292 million yuan), and Zhejiang Dongri (4.5 million yuan) [2] Market Capitalization - The average total market capitalization of stocks reaching historical highs was 120.84 billion yuan, while the average circulating market capitalization was 112.84 billion yuan [2] - The stocks with the highest total market capitalization included Agricultural Bank of China (2.308 trillion yuan), Postal Savings Bank of China (624.49 billion yuan), and Cambrian (433.41 billion yuan) [2] - Stocks with lower market capitalizations included Qianjin Technology (1.449 billion yuan) and Sanxiang Technology (2.147 billion yuan) [2] Historical Highs - Agricultural Bank of China recorded 15 instances of reaching historical highs in the past month, while Xinzuobiao and Zhejiang Zhengte had 11 instances each [2]